248 related articles for article (PubMed ID: 11757204)
1. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
2. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
6. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
Neville-Webbe Hl; Coleman RE
Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Wellington K; Goa KL
Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
[TBL] [Abstract][Full Text] [Related]
8. Safety and convenience of a 15-minute infusion of zoledronic acid.
Berenson J; Hirschberg R
Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
[TBL] [Abstract][Full Text] [Related]
9. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
14. New advances in the biology and treatment of myeloma bone disease.
Berenson JR
Semin Hematol; 2001 Apr; 38(2 Suppl 3):15-20. PubMed ID: 11309704
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis.
Yang L; Du S
Medicine (Baltimore); 2015 Oct; 94(42):e1822. PubMed ID: 26496320
[TBL] [Abstract][Full Text] [Related]
17. Clinical research update: zoledronate.
Body JJ
Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
[TBL] [Abstract][Full Text] [Related]
18. Management of bone metastases in breast cancer.
Lipton A
Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
[TBL] [Abstract][Full Text] [Related]
19. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Harvey HA
Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate therapy in multiple myeloma: past, present, future.
Jantunen E
Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]